Application of cyclic dipeptide to improvement of barrier moisturizing and repairing

By promoting the expression of skin barrier factors FLG, AQP3, LOR, and IVL, cyclic (L-leucine-L-proline) dipeptide and cyclic (D-leucine-L-proline) dipeptide address the problem of weakened skin barrier function, achieving skin moisturizing and repair effects.

CN118902901AActive Publication Date: 2024-11-08SHANGHAI JAHWA UNITED
View PDF 10 Cites 0 Cited by

Patent Information

Application Number
CN202411296179.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-14
Publication Date
2024-11-08
Estimated Expiration
2044-09-14

AI Technical Summary

Technical Problem

Existing technologies have failed to effectively utilize the activity of cyclic (L-leucine-L-proline) dipeptides and cyclic (D-leucine-L-proline) dipeptides in cosmetic and skincare research. Weakened skin barrier function leads to problems such as dry skin, roughness, pigmentation, and aging.

Method used

Cyclic (L-leucine-L-proline) dipeptide and cyclic (D-leucine-L-proline) dipeptide were used to promote the expression of skin barrier-related factors FLG, AQP3, LOR, and IVL, thereby improving skin moisturizing function.

Benefits of technology

It significantly enhances the expression of skin barrier factors, improves skin hydration, strengthens the skin barrier function, prevents moisture loss, and improves skin health.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005047381630000041
    Figure BDA0005047381630000041
  • Figure BDA0005047381630000051
    Figure BDA0005047381630000051
  • Figure BDA0005047381630000091
    Figure BDA0005047381630000091
Patent Text Reader

Abstract

The invention provides application of cyclic dipeptide in improving moisturizing and repairing of a barrier. The cyclic dipeptide is selected from cyclic (L-leucine-L-proline) dipeptide, cyclic (D-leucine-L-proline) dipeptide or a combination of the cyclic (L-leucine-L-proline) dipeptide and the cyclic (D-leucine-L-proline) dipeptide. The barrier moisturizing and repairing improvement is achieved by promoting expression of skin barrier related factors FLG, AQP3, LOR and / or IVL. The invention also relates to an application of the cyclic dipeptide in preparation of an external skin preparation with barrier improving, moisturizing and repairing effects. The external skin preparation is selected from face cream, emulsion, gel, toning lotion, essence, mask, eye cream, aerosol cleaning foam, spray, shower gel or facial cleanser.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the application of cyclic dipeptides, and specifically relates to cyclic dipeptides with the function of improving barrier moisturizing and repairing. The structure of the cyclic dipeptide is cyclic (L-leucine-L-proline) dipeptide and / or cyclic (D-leucine-L-proline) dipeptide, which has the function of promoting the expression of skin barrier moisturizing factors such as FLG, AQP3, LOR, IVL, etc., and can be used as an ingredient for improving barrier moisturizing and repairing in cosmetics, food or medicine. Background Art

[0002] The skin is the largest organ in the human body, accounting for about 16% of the body weight. It is also the first line of defense against external adverse factors and plays a role in protecting internal tissues and organs. The skin has a protective effect against external environmental stimuli, such as physical barriers to ultraviolet rays and harmful substances. The skin prevents excessive water loss, maintains the water content of the stratum corneum, and regulates the moisture content of the skin. The normal water content of the skin is 20% to 35%. When the water content of the skin drops below 10%, the barrier function of the skin is damaged. When the skin barrier is damaged, dry skin, rough skin, pigmentation, wrinkles and aging may occur. Therefore, protecting the skin, maintaining the barrier function of the skin, and improving the moisturizing effect of the skin are of great significance to skin care products.

[0003] The structural basis of the skin barrier is the stratum corneum formed by the keratinocytes on the surface, the lipids between the keratinocytes, and the natural protective factors, which is the so-called "brick wall theory", the stratum corneum and its keratin capsule (bricks and mud) and the lipid bilayer between cells (plaster). The formation of the stratum corneum involves many important proteins, including filaggrin (FLG), involucrin (IVL), loricrin (LOR), keratinocyte transglutaminase, keratin 1 (K1) and keratin 10 (K10).

[0004] Filament protein FLG, also known as microfilament aggregation protein, is mainly present in the granular layer and transparent layer of the epidermis. It is converted from the inactive pFLG in the transparent keratin granules of the granular layer of the epidermis by catalysis of some specific phosphatases and proteases. It can interact with keratin intermediate filament protein and aggregate into keratin fiber bundles, thereby forming a flat scaffold structure of the outermost keratinocytes. Studies have shown that in patients with atopic dermatitis, FLG expression decreases, and the skin barrier function is weakened or impaired. Loricrin LOR is mainly expressed in the granular layer and stratum corneum and is the main component of terminally differentiated CE. The formation of the keratin capsule marks the production of keratinocytes, the end product of keratinocyte differentiation, and is the basis for the epidermis to serve as a defense barrier. Involucrin IVL is mainly expressed in the upper part of the spinous cell layer and the granular layer. It is a marker protein for keratinocyte differentiation. It is located in the outer layer of the cornified capsule and covalently binds to ceramide containing -OH, thereby connecting the lipid matrix and keratinocytes to play a role.

[0005] In the skin structure, although the stratum corneum is considered the most important physiological barrier, the basal layer of the epidermis is equally important for barrier function. Keratinocytes in the basal layer of the epidermis express aquaporin 3 (AQP3), which is a complete transmembrane protein channel. Water and glycerol in the body circulation can reach the epidermis through AQP3, promote the hydration of the stratum corneum, and are closely related to the skin's moisturizing barrier function.

[0006] Cyclic peptides are widely present in nature and have strong biological activity. Most of them can be used as drugs or drug precursors, playing an extremely important role in the life activities of organisms. Cyclic dipeptides are the smallest class of compounds among cyclic peptide members and are widely present in nature. Cyclic dipeptides have a diketopiperazine structure and therefore have high stability. The special spatial conformation of cyclic dipeptides gives them obvious physiological activity and has many potential application values ​​in the fields of chemistry, medicinal chemistry, biochemistry, life sciences, etc., so they have attracted the attention of many chemists, biologists and pharmacists at home and abroad.

[0007] Applicants are particularly interested in cyclic (L-Leucine-L-Proline) dipeptides and cyclic dipeptides (D-Leucine-L-Proline) dipeptides.

[0008] Cyclic (L-leucine-L-proline) dipeptide is a microbial metabolite that can be metabolized and produced in many bacteria, fungi and actinomycetes. Qi Shuhua et al. isolated cyclic (L-leucine-L-proline) compounds from the metabolites of marine bacteria Pseudomonas sp. (Qi Shuhua, Qian Peiyuan, Zhang Si, Research on antimicrobial metabolites of marine bacteria Pseudomonas sp. [J], Natural Product Research and Development, 2009, 21(3): 420-423); Wu Xiuli et al. isolated this substance from the liquid culture of Pseudomonas pyrophyll (Wu Xiuli, Lin Sheng, Zhu Chenggen et al., Research on the chemical composition of the liquid culture of Pseudomonas pyrophyll [J], Chinese Journal of Traditional Chinese Medicine, 2011, 36(7): 874-880); Li Haifeng et al. also isolated this compound from Bacillus subtilis 7Ze3 (Li Haifeng, Ye Yong Hao, Guo Jianhua, Isolation and Identification of Cyclic Dipeptide from Bacillus subtilis 7Ze3 [J], Jiangsu Agricultural Science, 2010 (2): 107-109); Wang Jing et al. reported that cyclic (L-leucine-L-proline) dipeptide was isolated from endophytic fungi of Platycladus orientalis (Wang Jing, Wei Yan, Yi Xiaohua et al., Investigation of Herbicidal Selectivity of Endophytic Fungi J46 of Platycladus orientalis and Isolation of Active Substances [C], Proceedings of the 13th National Pesticide Teaching and Research Symposium, 2013: 260-266). Zhu Jiansheng et al. isolated cyclic (D-leucine-L-proline) compounds from marine bacteria (Zhu Jiansheng, Study on Cyclic Dipeptide and Its Biological Activity in Marine Bacteria Pseudomonas putida [D], Jiangsu: Yangzhou University, 2013).

[0009] However, none of these documents studies or mentions the activity research of cyclo(L-leucine-L-proline) dipeptide and / or cyclo(D-leucine-L-proline) dipeptide in beauty and skin care.

[0010] The present invention unexpectedly discovered that cyclic (L-leucine-L-proline) dipeptide and / or cyclic (D-leucine-L-proline) dipeptide has the effect of promoting the expression of skin barrier moisturizing factors such as FLG, AQP3, LOR, IVL, etc., and can be used as an ingredient for improving barrier and moisturizing in cosmetics, food or medicine. Summary of the invention

[0011] On the one hand, the present invention relates to the use of cyclic dipeptides to improve barrier moisturizing and repair, wherein the cyclic dipeptide is selected from: cyclic (L-leucine-L-proline) dipeptide, cyclic (D-leucine-L-proline) dipeptide or a combination thereof.

[0012] In a preferred embodiment, the improvement of barrier moisturizing repair is achieved by promoting the expression of skin barrier related factors FLG, AQP3, LOR and / or IVL.

[0013] In a preferred embodiment, the cyclic dipeptide is used at a concentration of 2.5 ppm to 40 ppm. In a preferred embodiment, the cyclic dipeptide is used at a concentration of 10 ppm to 40 ppm, 2.5 ppm to 20 ppm, or 4 ppm.

[0014] On the other hand, the present invention relates to the use of a cyclic dipeptide in the preparation of a skin topical preparation having the effect of improving barrier moisturizing and repairing, wherein the cyclic dipeptide is selected from: cyclic (L-leucine-L-proline) dipeptide, cyclic (D-leucine-L-proline) dipeptide or a combination thereof.

[0015] In a preferred embodiment, the skin external preparation is selected from the following forms: facial cream, lotion, gel, toner, essence, facial mask, eye cream, aerosol cleansing foam, spray, shower gel, or facial cleanser. DETAILED DESCRIPTION OF THE INVENTION

[0017] Unless otherwise defined, all technical and scientific terms used herein have the same meanings as commonly understood by those of ordinary skill in the art to which the invention belongs. Although any methods and materials similar or equivalent to those described herein can be used to implement or test the present invention, preferred methods and materials are described herein. For purposes of the present invention, the following terms are defined below.

[0018] As used herein, the term "about" refers to an amount, level, value, dimension, size, or amount that differs by up to 30%, 20%, or 10% compared to the amount, level, value, dimension, size, or amount of a reference product. Percentages used herein, unless otherwise indicated, are by weight.

[0019] Throughout the specification and claims, unless otherwise required, the following words "comprise" and variations "comprising" and "including" will be understood to imply the inclusion of a stated integer or step, or a group of integers or steps, but not the exclusion of any other integer or step, or other group of integers or steps.

[0020] The present invention is based on the following unexpected discovery: cyclic (L-leucine-L-proline) dipeptide and / or cyclic (D-leucine-L-proline) dipeptide has the function of promoting the expression of skin barrier moisturizing factors such as FLG, AQP3, LOR, IVL, etc., and can be used as ingredients for improving barrier and moisturizing in cosmetics, food or medicine.

[0021] Cyclic dipeptide

[0022] The invention provides a cyclic dipeptide component, the structure of which is: cyclic (L-leucine-L-proline) dipeptide and / or cyclic (D-leucine-L-proline) dipeptide.

[0023] Table 1 shows the structural information of cyclo(L-leucine-L-proline) dipeptide and cyclo(D-leucine-L-proline) dipeptide.

[0024] Table 1

[0025]

[0026]

[0027] In a specific embodiment, the composition of the present invention uses cyclo(L-leucine-L-proline) dipeptide and cyclo(D-leucine-L-proline) dipeptide provided by Donghua University.

[0028] Skin topical products

[0029] The present invention also provides a skin external preparation, which comprises cyclic (L-leucine-L-proline) dipeptide and / or cyclic (D-leucine-L-proline) dipeptide.

[0030] The skin external preparation is a general concept for all ingredients usually used on the outside of the skin, for example, it can be a cosmetic composition or a pharmaceutical composition. The cosmetic composition can be basic cosmetics, facial makeup cosmetics, body cosmetics, hair care cosmetics, etc. There is no special restriction on its dosage form, and it can be reasonably selected according to different purposes.

[0031] Cyclic (L-leucine-L-proline) dipeptide and / or cyclo (D-leucine-L-proline) dipeptide can be added as cosmetic additives to essences, creams, lotions, eye creams, essential oils, massage oils and other cosmetics.

[0032] The cosmetic composition may also contain different media or matrix excipients permitted in cosmetics according to different dosage forms and purposes.

[0033] The cosmetic, dermatological or pharmaceutically acceptable excipients that can be used for the skin topical composition of the present invention are in the form of an aqueous phase, an oil phase, a gel, a wax-in-water emulsion, an oil-in-water emulsion or an oil-in-water emulsion. The aqueous phase is a mixture of one or more water-soluble or dispersible components, which can be liquid, semi-solid or solid at room temperature (25° C.). The excipient includes or can be in the form of a suspension, dispersion or solution in water or a water-alcohol excipient, which can contain a thickener or a gelling agent. Those skilled in the art can select a suitable product form based on the knowledge mastered by those skilled in the art, the components contained therein.

[0034] The composition may include an aqueous phase, which may contain water or a mixture of water and at least one hydrophilic organic solvent, such as an alcohol, especially a linear or branched lower monohydric alcohol containing 2 to 5 carbon atoms, such as ethanol or propanol; a polyol, such as propylene glycol, sorbitol, glycerol, panthenol or polyethylene glycol, and mixtures thereof.

[0035] When the composition of the invention is in the form of an emulsion, the composition may also optionally contain a surfactant.

[0036] The composition may also comprise a film-forming polymer, such as polyurethanes, polyacrylic acid homopolymers or copolymers, polyesters, hydrocarbon-based resins and / or silicone resins. The polymer may be dissolved or dispersed in a cosmetically acceptable vehicle and optionally combined with a plasticizer.

[0037] The composition of the present invention may further comprise any components commonly used in the cosmetic field. These components include preservatives, aqueous phase thickeners (extract biopolymers, synthetic polymers) and fat phase thickeners, fragrances, hydrophilic and lipophilic active agents and mixtures thereof.

[0038] The composition of the present invention may also contain an additional particulate phase, which may be a pigment and / or pearlescent agent and / or filler used in cosmetic compositions.

[0039] Pigments may be present in the composition, suitable inorganic pigments include titanium, zirconium and cerium oxides as well as zinc oxide, iron oxide and ferric blue; suitable organic pigments include barium, strontium, calcium and aluminium lakes and carbon black.

[0040] Pearlescent agents may be present in the composition. Suitable pearlescent agents include mica coated with titanium oxide, iron oxide or natural pigments.

[0041] Fillers may be present in the composition, suitable fillers include talc, silica, zinc stearate, mica, kaolin, nylon powder, polyethylene powder, Teflon, starch, boron nitride, copolymer microspheres, such as silicone resin microspheres.

[0042] The composition of the present invention can be formulated into any suitable product form. Such product forms include, but are not limited to, aerosol sprays, creams, emulsions, solids, liquids, dispersions, foams, gels, lotions, mousses, ointments, powders, patches, pomades, solutions, hand-pump sprays, sticks, facial masks, and wet wipes. The composition of the present invention can be conveniently used to prepare or as a cosmetic, dermatological, or pharmaceutical topical application product by various methods well known in the art.

[0043] The skin topical composition of the present invention may include one or more of the following ingredients: antiallergic agents, anti-inflammatory agents, moisturizers, antimicrobial agents, antioxidants, chelating agents, colorants, depigmenting agents, emollients, emulsifiers, exfoliants, film formers, fragrances, insect repellents, lubricants, pharmaceutically active agents, moisturizers, photostabilizers, preservatives, skin care agents, skin penetration enhancers, sunscreens, stabilizers, surfactants, thickeners, viscosity regulators, vitamins or any combination thereof. DETAILED DESCRIPTION

[0044] The present invention is further described below in conjunction with specific examples. However, the scope of the present invention is not limited to these embodiments, which are intended to illustrate the technical solution of the present invention and do not constitute a limitation of the scope of the present invention. The experimental methods in the following examples without specifying specific conditions are usually based on conventional conditions or conditions recommended by the manufacturer. Unless otherwise specified, all percentages and parts are based on mass.

[0045] Cyclic (L-leucine-L-proline) dipeptide (purity ≥ 98%), naturally extracted or chemically synthesized, provided by Donghua University.

[0046] Cyclic (D-leucine-L-proline) dipeptide (purity ≥ 98%), naturally extracted or chemically synthesized, provided by Donghua University.

[0047] Embodiment 1:

[0048] Cyclic (L-leucine-L-proline) dipeptide was accurately weighed and prepared with PBS phosphate buffer to a concentration of 400 ppm as the test stock solution.

[0049] Embodiment 2:

[0050] Cyclic (D-leucine-L-proline) dipeptide was accurately weighed and prepared with PBS phosphate buffer to a concentration of 400 ppm as the test stock solution.

[0051] Embodiment 3:

[0052] Example 1 was diluted with culture medium to prepare a concentration of 40 ppm as a test solution.

[0053] Embodiment 4:

[0054] Example 1 was diluted with culture medium to prepare a concentration of 20 ppm as a test solution.

[0055] Embodiment 5:

[0056] Example 1 was diluted with culture medium to prepare a concentration of 10 ppm as a test solution.

[0057] Embodiment 6:

[0058] Example 1 was diluted with culture medium to prepare a concentration of 5 ppm as a test solution.

[0059] Embodiment 7:

[0060] Example 1 was diluted with culture medium to prepare a concentration of 2.5 ppm as a test solution.

[0061] Embodiment 8:

[0062] Example 1 was diluted with culture medium to prepare a concentration of 4 ppm as a test solution.

[0063] Embodiment 9:

[0064] Example 2 was diluted with culture medium to prepare a concentration of 4 ppm as a test solution.

[0065] Test Example 1: Improvement of barrier and moisturizing gene expression - 2D cells

[0066] Materials and Reagents:

[0067] Keratinocytes (Batch No.: Ep23082203) were provided by Guangdong Boxi Biotechnology Co., Ltd.; KcGrowth culture medium (Guangdong Boxi Biotechnology), PBS (Solabo), RNAisoPlus (Acori Biotechnology), and reverse transcription kit (Acori Biotechnology).

[0068] Experimental equipment:

[0069] CO2 incubator (Thermo, 150I), clean bench (Sujing Antai, SW-CJ-1F), and fluorescence quantitative PCR instrument (BioRad, CFX-96).

[0070] Promote FLG expression

[0071] This test is based on keratinocytes, and detects the changes in the expression of FLG gene after the action of Example 3-7. A blank control group (BC) is set up, and Example 3-7 is the sample group.

[0072] Press 2.0×10 5 Inoculate cells into 6-well plates at a seeding density of 100 / well and incubate overnight in an incubator (37°C, 5% CO2). When the cell plating rate in the 6-well plate reaches 40% to 60%, group the drugs, with a dosage of 2.0 mL per well, 3 replicate wells per group, and incubate in an incubator (37°C, 5% CO2) for 24 hours. Discard the supernatant, wash twice with 1.0 mL / well PBS, add 1.0 mL RNAiso Plus to each well, blow and lyse the cells, and collect the samples. Extract RNA, reverse transcribe to cDNA, and perform fluorescence quantitative PCR detection using 2 -△△CTMethods The results were calculated. The results were expressed as mean ± SD. The sample group was compared with the BC group using t-test statistical analysis. All statistical analyses were two-tailed. P < 0.05 was considered to be significantly different, expressed as *; P < 0.01 was considered to be extremely significantly different, expressed as **.

[0073] Up-regulation rate (%) = (gene content sample group - gene content BC) / gene content BC × 100%.

[0074] The results are shown in Table 2.

[0075] Table 2: FLG gene expression detection results

[0076]

[0077] From the experimental results, it can be seen that compared with the blank group, the FLG gene expression of Examples 3-7 was significantly upregulated, with the upregulation rates being 23.00%, 30.00%, 32.00%, 84.00% and 86.00%, respectively, indicating that the cyclic dipeptide has a promoting effect on the FLG expression of keratinocytes in the range of 2.5ppm-40ppm, indicating that the cyclic dipeptide has the function of improving the skin barrier and repairing.

[0078] Promote AQP3 expression

[0079] qPCR was used to detect the changes of AQP3 gene in keratinocytes.

[0080] This test is based on keratinocytes, and detects the changes in the expression of the AQP3 gene after the action of Examples 3-7. A blank control group (BC) is set up, and Examples 3-7 are sample groups.

[0081] Press 2.0×10 5 Inoculate cells into 6-well plates at a seeding density of 100 / well and incubate overnight in an incubator (37°C, 5% CO2). When the cell plating rate in the 6-well plate reaches 40% to 60%, group the drugs, with a dosage of 2.0 mL per well, 3 replicate wells per group, and incubate in an incubator (37°C, 5% CO2) for 24 hours. Discard the supernatant, wash twice with 1.0 mL / well PBS, add 1.0 mL RNAiso Plus to each well, blow and lyse the cells, and collect the samples. Extract RNA, reverse transcribe to cDNA, and perform fluorescence quantitative PCR detection using 2 -△△CT Methods The results were calculated. The results were expressed as mean ± SD. The sample group was compared with the BC group using t-test statistical analysis. All statistical analyses were two-tailed. P < 0.05 was considered to be significantly different, expressed as *; P < 0.01 was considered to be extremely significantly different, expressed as **.

[0082] Up-regulation rate (%) = (gene content sample group - gene content BC) / gene content BC × 100%.

[0083] The results are shown in Table 3.

[0084] Table 3: AQP3 gene expression detection results

[0085]

[0086] From the experimental results, it can be seen that compared with the blank group, the AQP3 gene expression of Examples 3-5 was significantly upregulated, with upregulation rates of 38.00%, 61.00%, and 83.00%, respectively, indicating that the cyclic dipeptide has a promoting effect on the AQP3 expression of keratinocytes in the range of 10ppm-40ppm. The AQP3 gene expression of Examples 6-7 is equivalent to that of the blank group, indicating that the cyclic dipeptide has no effect on the AQP3 gene expression at concentrations of 5ppm and 2.5ppm. The above results show that the cyclic dipeptide has the function of moisturizing and repairing the skin.

[0087] Promote LOR expression

[0088] qPCR was used to detect the changes of LOR genes in keratinocytes.

[0089] This test is based on keratinocytes, and detects the changes in LOR gene expression after the action of Example 3-7. A blank control group (BC) is set up, and Example 3-7 is a sample group.

[0090] Press 2.0×10 5 Inoculate cells into 6-well plates at a seeding density of 100 / well and incubate overnight in an incubator (37°C, 5% CO2). When the cell plating rate in the 6-well plate reaches 40% to 60%, group the drugs, with a dosage of 2.0 mL per well, 3 replicate wells per group, and incubate in an incubator (37°C, 5% CO2) for 24 hours. Discard the supernatant, wash twice with 1.0 mL / well PBS, add 1.0 mL RNAiso Plus to each well, blow and lyse the cells, and collect the samples. Extract RNA, reverse transcribe to cDNA, and perform fluorescence quantitative PCR detection using 2 -△△CT Methods The results were calculated. The results were expressed as mean ± SD. The sample group was compared with the BC group using t-test statistical analysis. All statistical analyses were two-tailed. P < 0.05 was considered to be significantly different, expressed as *; P < 0.01 was considered to be extremely significantly different, expressed as **.

[0091] Up-regulation rate (%) = (gene content sample group - gene content BC) / gene content BC × 100%.

[0092] The results are shown in Table 4.

[0093] Table 4: LOR gene expression detection results

[0094]

[0095] From the experimental results, it can be seen that compared with the blank group, the LOR gene expression levels of Examples 3-7 were significantly upregulated, with the upregulation rates being 51.00%, 87.00%, 95.00%, 99.00% and 135.00%, respectively, indicating that the cyclic dipeptide has a promoting effect on the LOR expression of keratinocytes in the range of 2.5ppm-40ppm, indicating that the cyclic dipeptide has the function of improving the skin barrier and repairing.

[0096] Promote IVL expression

[0097] qPCR was used to detect the changes of IVL genes in keratinocytes.

[0098] This test is based on keratinocytes, and detects the changes in the expression of IVL gene after the action of Examples 3-7. A blank control group (BC) is set up, and Examples 3-7 are the sample groups.

[0099] Press 2.0×10 5 Inoculate cells into 6-well plates at a seeding density of 100 / well and incubate overnight in an incubator (37°C, 5% CO2). When the cell plating rate in the 6-well plate reaches 40% to 60%, group the drugs, with a dosage of 2.0 mL per well, 3 replicate wells per group, and incubate in an incubator (37°C, 5% CO2) for 24 hours. Discard the supernatant, wash twice with 1.0 mL / well PBS, add 1.0 mL RNAiso Plus to each well, blow and lyse the cells, and collect the samples. Extract RNA, reverse transcribe to cDNA, and perform fluorescence quantitative PCR detection using 2 -△△CT Methods The results were calculated. The results were expressed as mean ± SD. The sample group was compared with the BC group using t-test statistical analysis. All statistical analyses were two-tailed. P < 0.05 was considered to be significantly different, expressed as *; P < 0.01 was considered to be extremely significantly different, expressed as **.

[0100] Up-regulation rate (%) = (gene content sample group - gene content BC) / gene content BC × 100%.

[0101] The results are shown in Table 5.

[0102] Table 5: IVL gene expression test results

[0103]

[0104] From the experimental results, it can be seen that compared with the blank group, the IVL gene expression of Example 3 was significantly upregulated, with an upregulation rate of 50.00%, indicating that the cyclic dipeptide has a promoting effect on the IVL expression of keratinocytes at a concentration of 40ppm. The IVL gene expression of Examples 4-7 is equivalent to that of the blank group, indicating that the cyclic dipeptide has no effect on IVL gene expression at a concentration of 2.5ppm-20ppm. The above results show that the cyclic dipeptide has the function of improving skin barrier and repairing.

[0105] Test Example 2: Improvement of barrier function—promoting the expression of FLG and LOR on 3D skin model

[0106] This test is based on a 3D epidermal model to detect changes in the expression of FLG and LOR genes after the action of Examples 8-9. A blank control group (BC) and a model group (NC) were set up, and Examples 8-9 were the sample group.

[0107] 1. Test materials, reagents and main equipment

[0108] EpiKutis 3D epidermal skin model, PBS, DMSO (Sigma), culture medium (Gibco), PolyI:C (Sigma), lipopolysaccharide (E.Coli.Sigma), RNAiso Plus (TaKaRa), reverse transcription kit (TaKaRa).

[0109] CO2 incubator (Thermo), clean bench (Sujing Antai), inverted microscope (Olympus), high-speed refrigerated centrifuge (Changsha Xiangyi), real-time fluorescence quantitative PCR instrument (BIO-RAD), digital display constant temperature water bath (Changzhou Guohua).

[0110] 2. Experimental methods:

[0111] PolyI:C+LPS induction working solution: Take 1.44mL 5mg / mL PolyI:C stock solution and 3mL 2mg / mL LPS stock solution, dissolve in the culture medium, the total volume is 300mL, so that the final concentration of PolyI:C is 24μg / mL, and the final concentration of LPS is 20μg / mL.

[0112] The skin model was transferred to a 6-well plate according to the grouping (a small mold was added in advance, and 3.7 mL of culture solution was added), and the test group number was marked on the 6-well plate. The BC group and the NC group added culture solution, and the sample group evenly distributed Examples 8-9 on the surface of the model and placed in a CO2 incubator (37°C, 5% CO2) for incubation for 24 hours. After the drug administration and incubation were completed, the 6-well plate was removed from the incubator, the surface of the skin model was cleaned with sterile PBS, and the residual PBS liquid was wiped with a sterile cotton swab. Polyl:C and LPS induction working solution were added to the NC group and the sample group, and culture solution was added to the BC group. After the end, the 6-well plate was placed in a CO2 incubator (37°C, 5% CO2) and incubated for 24 hours. The model culture solution was collected in a centrifuge tube. After collecting the sample, RNA extraction, reverse transcription and fluorescence quantitative PCR detection were carried out according to the instructions of the kit, using 2 -△△CT Methods The results were calculated. t-test was used for statistical analysis among the groups, p<0.05 indicated significant difference, p<0.01 indicated extremely significant difference.

[0113] Table 6: FLG gene detection results of 3D skin model

[0114]

[0115] According to the results in Table 6, after model induction, the expression of FLG decreased compared with the normal group, while the expression of FLG increased significantly after the sample was given. The results showed that the cyclic (L-leucine-L-proline) dipeptide of Example 8 and the cyclic (D-leucine-L-proline) dipeptide of Example 9 at a concentration of 4ppm can significantly increase the expression of the barrier factor FLG gene, and the increase rates are 49.21% and 71.43%, respectively, indicating that the cyclic (L-leucine-L-proline) dipeptide and the cyclic (D-leucine-L-proline) dipeptide can improve the skin barrier and repair function by promoting FLG expression.

[0116] Table 7: LOR gene detection results of 3D skin model

[0117]

[0118] According to the results in Table 7, after model induction, the LOR expression level was lower than that of the normal group, and the LOR expression level was significantly increased after the sample was given. The results showed that the Example 8 cyclic (L-leucine-L-proline) dipeptide and the Example 9 cyclic (D-leucine-L-proline) dipeptide at a concentration of 4ppm can significantly increase the expression of the barrier factor LOR gene, and the increase rate reached 98.46% and 87.69% respectively, indicating that the cyclic (L-leucine-L-proline) dipeptide and the cyclic (D-leucine-L-proline) dipeptide can improve the skin barrier and repair function by promoting LOR expression.

[0119] Application Examples

[0120] Cyclic (L-leucine-L-proline) dipeptide and cyclic (D-leucine-L-proline) dipeptide can be used for the preparation of external skin preparations.

[0121] The skin external preparation is preferably a cosmetic composition, such as a cream, lotion, gel, toner, essence, mask, eye cream, aerosol (cleansing foam), spray, shower gel, facial cleanser, etc. The weight percentage of cyclo(L-leucine-L-proline) dipeptide and cyclo(D-leucine-L-proline) dipeptide in the skin external preparation is 0.0001%-20% (w / w). The preferred weight percentage is 0.1%-10% (w / w). The more preferred weight percentage is 0.01%-5% (w / w). The most preferred weight percentage is 0.1%-5% (w / w).

[0122] The following are specific application examples of cyclo(L-leucine-L-proline) dipeptide and cyclo(D-leucine-L-proline) dipeptide in skin external preparations, and the formulations and preparation methods of these preparations. In the following tables, "-" means no addition.

[0123] Application Example 1: Preparation of facial cream

[0124]

[0125] Application Example 2: Preparation of Emulsion

[0126]

[0127]

[0128] Application Example 3: Preparation of Gel

[0129]

[0130]

[0131] Application Example 4: Preparation of lotion

[0132]

[0133] Application Example 5: Preparation of Essence

[0134]

[0135]

[0136] Application Example 6: Preparation of facial mask

[0137]

[0138]

[0139] Application Example 7: Preparation of Eye Cream

[0140]

[0141] Application Example 8: Preparation of Aerosol (Cleaning Bubble)

[0142]

[0143]

[0144] Application Example 9: Preparation of Spray

[0145]

[0146] Application Example 10: Preparation of Shower Gel

[0147]

[0148]

[0149] Application Example 11: Preparation of facial cleanser

[0150]

[0151]

Claims

1. Application of cyclic dipeptides to improve barrier moisturizing and repair, wherein the cyclic dipeptide is selected from: cyclic (L-leucine-L-proline) dipeptide, cyclic (D-leucine-L-proline) dipeptide or a combination thereof.

2. The use according to claim 1, wherein: The improved barrier moisturizing repair is achieved by promoting the expression of skin barrier related factors FLG, AQP3, LOR and / or IVL.

3. The use according to claim 1, wherein: The cyclic dipeptide is a cyclic (L-leucine-L-proline) dipeptide.

4. The use according to claim 1, wherein: The cyclic dipeptide is a cyclo(D-leucine-L-proline) dipeptide.

5. The use according to claim 1, characterized in that The cyclic dipeptide is used at a concentration of 2.5 ppm to 40 ppm.

6. The use according to claim 5, characterized in that The cyclic dipeptide is used at a concentration of 10 ppm to 40 ppm.

7. The use according to claim 5, characterized in that The cyclic dipeptide is used at a concentration of 2.5 ppm to 20 ppm.

8. The use according to claim 1, characterized in that The cyclic dipeptide was used at a concentration of 4 ppm.

9. Use of a cyclic dipeptide in the preparation of a skin topical preparation having barrier-improving, moisturizing and repairing effects, wherein the cyclic dipeptide is selected from: cyclic (L-leucine-L-proline) dipeptide, cyclic (D-leucine-L-proline) dipeptide or a combination thereof.

10. The skin external preparation according to claim 7, wherein the skin external preparation is selected from the following forms: facial cream, emulsion, gel, lotion, essence, facial mask, eye cream, aerosol cleansing foam, spray, shower gel, or facial cleanser.

Citation Information

Patent Citations

  • Moisturizing and brightening composition and application thereof

    CN110292542A

  • Formula applied to dendrobium officinale repair and sunscreen cream and preparation method

    CN111686057A

  • Polypeptide with skin barrier repairing function and application thereof

    CN113929750A

  • Cosmetic composition for strenging skin barrier and removing moisture containing

    CN115607474A

  • Application of cyclic (D-leucine-L-proline) dipeptide and plant bacteriostatic agent of cyclic (D-leucine-L-proline) dipeptide

    CN116439250A